First Eagle Investment Management LLC Buys Shares of 233,202 Beta Bionics, Inc. $BBNX

First Eagle Investment Management LLC purchased a new stake in shares of Beta Bionics, Inc. (NASDAQ:BBNX) during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 233,202 shares of the company’s stock, valued at approximately $4,634,000. First Eagle Investment Management LLC owned 0.53% of Beta Bionics at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of BBNX. Quantbot Technologies LP purchased a new stake in Beta Bionics during the third quarter valued at $286,000. TD Asset Management Inc grew its stake in shares of Beta Bionics by 50.7% during the 3rd quarter. TD Asset Management Inc now owns 60,076 shares of the company’s stock valued at $1,194,000 after purchasing an additional 20,200 shares during the period. EverSource Wealth Advisors LLC grew its stake in shares of Beta Bionics by 203.6% during the 3rd quarter. EverSource Wealth Advisors LLC now owns 2,377 shares of the company’s stock valued at $47,000 after purchasing an additional 1,594 shares during the period. Ameritas Investment Partners Inc. increased its position in shares of Beta Bionics by 139.1% during the 3rd quarter. Ameritas Investment Partners Inc. now owns 3,202 shares of the company’s stock valued at $64,000 after purchasing an additional 1,863 shares during the last quarter. Finally, GSA Capital Partners LLP bought a new position in shares of Beta Bionics in the 3rd quarter worth approximately $295,000.

Wall Street Analysts Forecast Growth

Several brokerages recently issued reports on BBNX. Bank of America lowered shares of Beta Bionics from a “buy” rating to a “neutral” rating in a research report on Friday, January 9th. Stifel Nicolaus dropped their price target on shares of Beta Bionics from $25.00 to $22.00 and set a “buy” rating on the stock in a research note on Wednesday, February 18th. Truist Financial cut their price objective on shares of Beta Bionics from $37.00 to $25.00 and set a “buy” rating for the company in a research report on Monday, February 2nd. UBS Group raised Beta Bionics to a “strong-buy” rating in a report on Monday, February 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Beta Bionics in a research report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $23.20.

Trending Headlines about Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Recent operational/analyst context supports longer‑term upside — Beta Bionics beat EPS estimates in its Feb. 17 quarter and the consensus analyst view remains a “Moderate Buy” with a $23.20 average price target, providing a counterbalance to near‑term selling. MarketBeat coverage
• Neutral Sentiment: Short‑interest data published for early March shows implausible values (entries report “0 shares”/NaN and 0.0 days to cover), so there is no reliable signal from short sellers — treat reported short‑interest changes as inconclusive until corrected by exchanges or data providers.
• Negative Sentiment: A wave of small insider sell orders was disclosed in early March (including the CFO’s sale of 1,428 shares and several other executive sales at roughly $12.36 each). Multiple Form 4 filings and press coverage frame this as coordinated executive selling, which often pressures sentiment for small‑cap biotech/medical device stocks. TipRanks: Insiders Cash Out
• Negative Sentiment: A securities‑litigation firm (Faruqi & Faruqi, LLP) issued a shareholder reminder/investigation notice seeking investors who experienced losses, increasing legal and reputational risk and likely weighing on near‑term sentiment until the matter is clarified. GlobeNewswire: Faruqi & Faruqi notice

Insider Transactions at Beta Bionics

In other Beta Bionics news, CFO Stephen Feider sold 20,000 shares of the company’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $29.53, for a total value of $590,600.00. Following the completion of the transaction, the chief financial officer directly owned 42,614 shares in the company, valued at $1,258,391.42. This represents a 31.94% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, insider Mike Mensinger sold 7,800 shares of the stock in a transaction that occurred on Friday, January 2nd. The shares were sold at an average price of $29.61, for a total transaction of $230,958.00. Following the sale, the insider directly owned 82,952 shares of the company’s stock, valued at approximately $2,456,208.72. This trade represents a 8.59% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 34,352 shares of company stock valued at $941,569.

Beta Bionics Price Performance

Shares of NASDAQ BBNX opened at $11.38 on Thursday. The stock has a market cap of $505.04 million, a PE ratio of -5.84 and a beta of 5.60. Beta Bionics, Inc. has a 1 year low of $8.89 and a 1 year high of $32.71. The firm has a fifty day moving average price of $18.35 and a 200-day moving average price of $22.35.

Beta Bionics (NASDAQ:BBNX) last issued its earnings results on Tuesday, February 17th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.42) by $0.12. Beta Bionics had a negative net margin of 73.02% and a negative return on equity of 20.29%. The company had revenue of $32.12 million during the quarter.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual‐hormone modes.